Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings.

RATIONALE AND OBJECTIVES We investigated the tumor specificity of gadolinium mesoporphyrin (Gd-MP) and manganese tetraphenylporphyrin (Mn-TPP) as magnetic resonance (MR) imaging contrast agents. METHODS Fifteen rats with multiple hepatocellular carcinomas and eight rats with implanted Novikoff hepatomas were given intravenous injections of either Gd-MP or Mn-TPP at 0.05 mmol/kg, which was compared with nonspecific gadopentetate dimeglumine (0.3 mmol/kg). T1-weighted spin-echo images were obtained before and up to 48 hr after injection and compared with corresponding microangiograms and histologic specimens. The relative enhancement of organs and tumors was plotted as a function of time. RESULTS Initially, both metalloporphyrins behaved as nonspecific agents, similar to gadopentetate dimeglumine, and enhanced the tumor by perfusion and diffusion. However, metalloporphyrins, but not gadopentetate dimeglumine, caused a delayed (> or = 3 hr) enhancement in some compartments of certain lesions. The MR imaging-microangiography-histology matching technique revealed that those compartments were actually nonviable components, including necrosis (n = 10), thrombosis (n = 7), and cystic secretion (n = 3), but not viable tumor tissue. CONCLUSION Metalloporphyrins did not prove to be tumor specific. However, the observed affinity for nonviable tissue has elicited other potential applications for these agents.

[1]  J. Tulip,et al.  Experimental laser phototherapy of the morris 7777 hepatoma in the rat , 1985, Hepatology.

[2]  S. H. Koenig,et al.  Tissue distribution and stability of metalloporphyrin MRI contrast agents , 1987, Magnetic resonance in medicine.

[3]  C J Gomer,et al.  Photodynamic therapy in the treatment of malignancies. , 1989, Seminars in hematology.

[4]  F. Starr,et al.  Hepatic Contrast–Enhancing Properties of Manganese–Mesoporphyrin and Manganese–TPPS4: A Comparative Magnetic Resonance Imaging Study in Rats , 1992, Investigative radiology.

[5]  M. Pantelides,et al.  A COMPARISON OF SERUM KINETICS AND TISSUE DISTRIBUTION OF PHOTOFRIN II FOLLOWING INTRAVENOUS AND INTRAPERITONEAL INJECTION IN THE MOUSE , 1989, Photochemistry and photobiology.

[6]  M W Berns,et al.  In vitro photosensitization I. Cellular uptake and subcellular localization of mono‐L‐aspartyl chlorin e6, chloro‐aluminum sulfonated phthalocyanine, and photofrin II , 1989, Lasers in surgery and medicine.

[7]  S. H. Koenig,et al.  The anomalous relaxivity of Mn3+(TPPS4) , 1987, Magnetic resonance in medicine.

[8]  W. A. Murphy,et al.  Magnetic resonance imaging using gadolinium labeled monoclonal antibody. , 1985, Investigative radiology.

[9]  A L Baert,et al.  Magnetic resonance imaging, microangiography, and histology in a rat model of primary liver cancer. , 1992, Investigative radiology.

[10]  T. Dougherty,et al.  Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. , 1981, Cancer research.

[11]  D Revel,et al.  Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging. A study of human carcinoma, lymphoma, and fibrosarcoma in mice. , 1987, Investigative radiology.

[12]  J. Sessler,et al.  Preclinical Evaluation of Gadolinium (III) Texaphyrin Complex: A New Paramagnetic Contrast Agent for Magnetic Resonance Imaging , 1994, Investigative radiology.

[13]  Q. Pan,et al.  Photodynamic effect of hematoporphyrin on human cancer cells and normal diploid fibroblasts in vitro. , 1985, Advances in experimental medicine and biology.

[14]  K. Hossmann,et al.  Proton relaxation enhancement in experimental brain tumors--in vivo NMR study of manganese(III)TPPS in rat brain gliomas. , 1990, Magnetic resonance imaging.

[15]  R. Lauffer,et al.  Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design , 1987 .

[16]  U Schmiedl,et al.  Metalloporphyrins as tumor-seeking MRI contrast media and as potential selective treatment sensitizers. , 1990, Investigative radiology.

[18]  J. Winkelman,et al.  The concentration in tumor and other tissues of parenterally administered tritium- and 14-C-labeled tetraphenylporphinesulfonate. , 1967, Cancer research.

[19]  Thierry Patrice,et al.  Tetra‐p‐aminophenylporphyrin conjugated with Gd‐DTPA: Tumor‐specific contrast agent for MR imaging , 1993, Journal of magnetic resonance imaging : JMRI.

[20]  F. Figge,et al.  Cancer Detection and Therapy. Affinity of Neoplastic, Embryonic, and Traumatized Tissues for Porphyrins and Metalloporphyrins.∗ , 1948, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[21]  J. S. Cohen,et al.  Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging , 1984, FEBS letters.

[22]  T J Dougherty,et al.  CHARACTERIZATION OF INTRA‐TUMORAL PORPHYRIN FOLLOWING INJECTION OF HEMATOPORPHYRIN DERIVATIVE OR ITS PURIFIED COMPONENT * , 1987, Photochemistry and photobiology.

[23]  R Weissleder,et al.  Drug targeting in magnetic resonance imaging. , 1992, Magnetic resonance quarterly.

[24]  J S Cohen,et al.  Metalloporphyrin magnetic resonance contrast agents. Feasibility of tumor-specific magnetic resonance imaging. , 1990, Acta radiologica. Supplementum.

[25]  W. Ebert,et al.  The Demonstration of Human Tumors on Nude Mice Using Gadolinium‐Labelled Monoclonal Antibodies for Magnetic Resonance Imaging , 1993, Investigative radiology.

[26]  R. van Hillegersberg,et al.  Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. , 1992, Gastroenterology.

[27]  P. Furmanski,et al.  Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. , 1988, Cancer research.

[28]  J Moan,et al.  A comparison of different photosensitizing dyes with respect to uptake C3H-tumors and tissues of mice. , 1987, Cancer letters.

[29]  Y. Ni,et al.  Role of Contrast Agent Perfusion and of Diffusion in the NMR Signal Enhancement of Liver Lesions , 1992, Journal of computer assisted tomography.

[30]  U Schmiedl,et al.  Porphyrins as contrast media , 1991, Magnetic resonance in medicine.

[31]  T. Dougherty,et al.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. , 1979, Cancer research.

[32]  R. Brasch New directions in the development of MR imaging contrast media. , 1992, Radiology.

[33]  H. Pass,et al.  Photodynamic therapy in oncology: mechanisms and clinical use. , 1993, Journal of the National Cancer Institute.

[34]  G. Marchal,et al.  Metalloporphyrin enhanced magnetic-resonance-imaging of acute myocardial-infarction , 1994 .

[36]  U. Schmiedl,et al.  Pharmaceutical Properties, Biodistribution, and Imaging Characteristics of Manganese-Mesoporphyrin: A Potential Hepatobiliary Contrast Agent for Magnetic Resonance Imaging , 1993, Investigative radiology.

[37]  P. Alderson,et al.  Mn (III) hematoporphyrin. A potential MR contrast agent. , 1990, Investigative radiology.